NetScientific PLC
VC Fund
London, United Kingdom
NetScientific plc (AIM: NSCI) is an investment and commercialisation group with an international portfolio of innovative life science, sustainability and technology companies.NetScientific identifies, invests in, and builds high growth companies in the UK and internationally. The company adds value through the proactive management of itsportfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events. NetScientific differentiates itself by employing a capital-light investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio. NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries NetScientific PLC invests in
Stages NetScientific PLC invests in
Countries NetScientific PLC invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Medical 4 (29%)
- Health Care 3 (21%)
- Biotechnology 2 (14%)
- Finance 1 (7%)
- Computer 1 (7%)
Stage
- Venture - Series Unknown 4 (29%)
- Seed 2 (14%)
- Funding Round 2 (14%)
- Series A 1 (7%)
- Debt Financing 1 (7%)
Country
- United Kingdom 5 (36%)
- United States 2 (14%)
- Israel 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Dr Ilian Iliev
Chief Executive Officer
|
Chief Executive Officer | Total investments: 15 | Find email | |
Farad Azima
CEO & Founder
|
CEO & Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Vortex Biosciences is an oncology diagnostics company that integrates cancer biology, microfluidic engineering and informatics to deliver better tools for isolating and characterizing circulating tumor cells (CTCs). Vortex’s first product, the VTX-1 Liquid Biopsy System, automates the label free isolation and collection of viable CTCs directly fromwhole blood. | $4.1M / Venture - Series Unknown / Jun 22, 2023 | ||
| Sofant is developing a low cost RF MEMS technology that solves power consumption and heat problems in high frequency phased array antenna systems. | $5M / Venture - Series Unknown / Nov 29, 2022 | ||
| EpiBone is a revolutionary bone reconstruction company that allows patients to “grow their own bone”. EpiBone’s pioneering technology utilizes a scan of the patient’s bone defect and the patient’s own stem cells to construct and cultivate a defect-specific autologous-like living bone graft. EpiBone is strategically positioned to provide a superiorbone graft that will provide exact defect repair, a simplified surgical procedure, improved bone formation and regeneration, and shorter recovery times, without the complications of foreign body implantation, to the over 900,000 patients who undergo bone-related surgeries each year. | Venture - Series Unknown / Nov 26, 2022 | ||
| Vortex Biosciences is an oncology diagnostics company that integrates cancer biology, microfluidic engineering and informatics to deliver better tools for isolating and characterizing circulating tumor cells (CTCs). Vortex’s first product, the VTX-1 Liquid Biopsy System, automates the label free isolation and collection of viable CTCs directly fromwhole blood. | $2.4M / Debt Financing / Aug 16, 2022 | ||
| Q-BOT Ltd, a Wandsworth, London, UK-based developer of a robotics platform that can access, survey, evaluate and apply treatments in a wide range of industries and applications. The company is funded through a combination of government grants, private investment and sales revenue, and has been supported by Climate-KIC, The Technology Strategy Boardand The Department for Energy and Climate Change. | $2.1M / Jun 15, 2022 | ||
| Q-BOT Ltd, a Wandsworth, London, UK-based developer of a robotics platform that can access, survey, evaluate and apply treatments in a wide range of industries and applications. The company is funded through a combination of government grants, private investment and sales revenue, and has been supported by Climate-KIC, The Technology Strategy Boardand The Department for Energy and Climate Change. | $1.9M / Series A / Jun 14, 2022 | ||
| Vortex Biosciences is an oncology diagnostics company that integrates cancer biology, microfluidic engineering and informatics to deliver better tools for isolating and characterizing circulating tumor cells (CTCs). Vortex’s first product, the VTX-1 Liquid Biopsy System, automates the label free isolation and collection of viable CTCs directly fromwhole blood. | $370.3K / Corporate Round / May 06, 2022 | ||
| Q-BOT Ltd, a Wandsworth, London, UK-based developer of a robotics platform that can access, survey, evaluate and apply treatments in a wide range of industries and applications. The company is funded through a combination of government grants, private investment and sales revenue, and has been supported by Climate-KIC, The Technology Strategy Boardand The Department for Energy and Climate Change. | $1.7M / Dec 21, 2021 | ||
| Q-BOT Ltd, a Wandsworth, London, UK-based developer of a robotics platform that can access, survey, evaluate and apply treatments in a wide range of industries and applications. The company is funded through a combination of government grants, private investment and sales revenue, and has been supported by Climate-KIC, The Technology Strategy Boardand The Department for Energy and Climate Change. | $1.7M / Convertible Note / Dec 21, 2021 | ||
| Martlet Capital is an early-stage investor based in Cambridge, providing patient capital to deep technology and life science startups with high growth potential.They seek to support entrepreneurs with value beyond capital. They have experience of helping companies scale from first-round through to exit. Visit their website to take a look at howwe work and their investment focus. | $2M / Dec 13, 2021 | ||
| See all 14 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does NetScientific PLC invest in?
NetScientific PLC invests primarily in Medical, Health Care and Biotechnology startups, most often at Venture - Series Unknown and Seed stage. Most of the 14 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact NetScientific PLC?
Public channels for NetScientific PLC include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at NetScientific PLC?
The team at NetScientific PLC includes Dr Ilian Iliev (Chief Executive Officer) and Farad Azima (CEO & Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
